22 research outputs found
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.
BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362
Hyperspectral fluorescence imaging for cellular iron mapping in the in vitro model of Parkinson's disease
Parkinson's disease (PD) is characterized by progressive dopaminergic cell loss in the substantia nigra (SN) and elevated iron levels demonstrated by autopsy. Direct visualization of iron with live imaging techniques has not yet been successful. The aim of this study is to visualize and quantify the distribution of cellular iron using an intrinsic iron hyperspectral fluorescence signal. The 1-methyl-4-phenylpyridinium (MPP+)-induced cellular model of PD was established in SHSY5Y cells exposed to iron with ferric ammonium citrate (FAC, 100 ÏM). The hyperspectral fluorescence signal of iron was examined using a high-resolution dark-field optical microscope system with signal absorption for the visible/near infrared spectral range. The 6-h group showed heavy cellular iron deposition compared with the 1-h group. The cellular iron was dispersed in a small particulate form, whereas the extracellular iron was aggregated. In addition, iron particles were found to be concentrated on the cell membrane/edge of shrunken cells. The iron accumulation readily occurred in MPP+-induced cells, which is consistent with previous studies demonstrating elevated iron levels in the SN. This direct iron imaging could be applied to analyze the physiological role of iron, and its application might be expanded to various neurological disorders involving metals, such as copper, manganese, or zinc. © The Authors.1481sciescopu
A new family of 3-D optical orthogonal codes for optical CDMA systems with differential detection
Triazinylamidophosphate Oligonucleotides: Synthesis and Study of Their Interaction with Cells and DNA-Binding Proteins
Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: Does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial
Background The long-term results after second
generation everolimus eluting bioresorbable vascular
scaffold (Absorb BVS) placement in small vessels are
unknown. Therefore, we investigated the impact of
vessel size on long-term outcomes, after Absorb BVS
implantation.
Methods In ABSORB Cohort B Trial, out of the total
study population (101 patients), 45 patients were
assigned to undergo 6-month and 2-year angiographic
follow-up (Cohort B1) and 56 patients to have
angiographic follow-up at 1-year (Cohort B2). The prereference vessel diameter (RVD) was <2.5 mm (smallvessel group) in 41 patients (41 lesions) and â„2.5 mm
(large-vessel group) in 60 patients (61 lesions).
Outcomes were compared according to pre-RVD.
Results At 2-year angiographic follow-up no differences
in late lumen loss (0.29±0.16 mm vs 0.25±0.22 mm,
p=0.4391), and in-segment binary restenosis (5.3% vs
5.3% p=1.0000) were demonstrated between groups.
In the small-vessel group, intravascular ultrasound
analysis showed a significant increase in vessel area
(12.25±3.47 mm2 vs 13.09±3.38 mm2 p=0.0015),
scaffold area (5.76±0.96 mm2 vs 6.41±1.30 mm2
p=0.0008) and lumen area (5.71±0.98 mm2 vs 6.20
±1.27 mm2 p=0.0155) between 6-months and 2-year
follow-up. No differences in plaque composition were
reported between groups at either time point. At 2-year
clinical follow-up, no differences in ischaemia-driven
major adverse cardiac events (7.3% vs 10.2%,
p=0.7335), myocardial infarction (4.9% vs 1.7%,
p=0.5662) or ischaemia-driven target lesion
revascularisation (2.4% vs 8.5%, p=0.3962) were
reported between small and large vessels. No deaths or
scaffold thrombosis were observed.
Conclusions Similar clinical and angiographic outcomes
at 2-year follow-up were reported in small and large
vessel groups. A significant late lumen enlargement and
positi